Netherton Syndrome is a rare hereditary skin disorder that causes severe skin barrier defects, frequent infections, and a heightened susceptibility to allergies, asthma, and eczema. The drug is ...

Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have QRX003 applied ...

Quoin Pharmaceuticals (QNRX) announces interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subject being dosed twice-daily in Quoin’s ongoing ...

Netherton Syndrome is a rare and severe genetic disorder characterized by chronic skin inflammation and scaling. QRX003 contains a broad-spectrum serine protease inhibitor targeting kallikreins ...

Quoin Pharmaceuticals (QNRX) announces interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first ...

Targeting kallikreins, which are thought to lead to the clinical manifestations of Netherton Syndrome, could be an ideal approach.” Quoin CEO, Dr. Michael Myers, added, “Following our recent ...

Netherton Syndrome is a rare and severe genetic disorder characterized by chronic skin inflammation and scaling. QRX003 contains a broad-spectrum serine protease inhibitor targeting kallikreins, ...

today announces positive interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subject being dosed twice-daily in Quoin’s ongoing open label ...

We remain steadfast in our commitment to develop a safe and effective treatment for the Netherton Syndrome community.” About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a clinical ...

Quoin CEO, Dr. Michael Myers, said, “While cautioning that this is interim clinical data from a very limited number of subjects, we are very pleased to announce these early results from two of our ...